JPS6251616A - 糖質輸液剤 - Google Patents
糖質輸液剤Info
- Publication number
- JPS6251616A JPS6251616A JP18850785A JP18850785A JPS6251616A JP S6251616 A JPS6251616 A JP S6251616A JP 18850785 A JP18850785 A JP 18850785A JP 18850785 A JP18850785 A JP 18850785A JP S6251616 A JPS6251616 A JP S6251616A
- Authority
- JP
- Japan
- Prior art keywords
- palatinose
- fructose
- glucose
- infusion
- carbohydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 claims abstract description 40
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 36
- 229930091371 Fructose Natural products 0.000 claims abstract description 20
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 20
- 239000005715 Fructose Substances 0.000 claims abstract description 20
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims abstract description 19
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims abstract description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 18
- 239000008103 glucose Substances 0.000 claims abstract description 18
- 150000002772 monosaccharides Chemical class 0.000 claims abstract description 16
- 150000005846 sugar alcohols Chemical class 0.000 claims abstract description 13
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 6
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000811 xylitol Substances 0.000 claims abstract description 6
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 6
- 235000010447 xylitol Nutrition 0.000 claims abstract description 6
- 229960002675 xylitol Drugs 0.000 claims abstract description 6
- -1 maltose Chemical compound 0.000 claims abstract description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 4
- 150000002016 disaccharides Chemical class 0.000 claims abstract description 4
- 239000000600 sorbitol Substances 0.000 claims abstract description 4
- 238000001802 infusion Methods 0.000 claims description 39
- 235000014633 carbohydrates Nutrition 0.000 claims description 33
- 235000000346 sugar Nutrition 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 125000003071 maltose group Chemical group 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract description 12
- 230000003204 osmotic effect Effects 0.000 abstract description 5
- 239000000243 solution Substances 0.000 abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 5
- 208000013016 Hypoglycemia Diseases 0.000 abstract description 3
- 239000012153 distilled water Substances 0.000 abstract description 3
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 3
- 239000007924 injection Substances 0.000 abstract description 3
- 238000002347 injection Methods 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000000706 filtrate Substances 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000011369 resultant mixture Substances 0.000 abstract 1
- 230000001954 sterilising effect Effects 0.000 abstract 1
- 238000002156 mixing Methods 0.000 description 10
- 239000003978 infusion fluid Substances 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 8
- 230000036325 urinary excretion Effects 0.000 description 7
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 5
- 230000029142 excretion Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 102000000340 Glucosyltransferases Human genes 0.000 description 1
- 108010055629 Glucosyltransferases Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18850785A JPS6251616A (ja) | 1985-08-29 | 1985-08-29 | 糖質輸液剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18850785A JPS6251616A (ja) | 1985-08-29 | 1985-08-29 | 糖質輸液剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6251616A true JPS6251616A (ja) | 1987-03-06 |
| JPS6354691B2 JPS6354691B2 (enrdf_load_stackoverflow) | 1988-10-28 |
Family
ID=16224929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP18850785A Granted JPS6251616A (ja) | 1985-08-29 | 1985-08-29 | 糖質輸液剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6251616A (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004045312A1 (ja) * | 2002-11-18 | 2004-06-03 | Shin Mitsui Sugar Co., Ltd. | 血糖値上昇抑制剤及び体脂肪蓄積抑制剤並びに食用材料 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0441819U (enrdf_load_stackoverflow) * | 1990-08-08 | 1992-04-09 |
-
1985
- 1985-08-29 JP JP18850785A patent/JPS6251616A/ja active Granted
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004045312A1 (ja) * | 2002-11-18 | 2004-06-03 | Shin Mitsui Sugar Co., Ltd. | 血糖値上昇抑制剤及び体脂肪蓄積抑制剤並びに食用材料 |
| KR101018610B1 (ko) * | 2002-11-18 | 2011-03-02 | 미츠이 세이토 가부시키가이샤 | 혈당치 상승 억제제 및 체지방 축적 억제제, 그리고식용재료 |
| US9017744B2 (en) | 2002-11-18 | 2015-04-28 | Mitsui Sugar Co., Ltd. | Method of using isomaltulose to suppress blood glucose level increase |
| US9017745B2 (en) | 2002-11-18 | 2015-04-28 | Mitsui Sugar Co., Ltd. | Method of using isomaltulose to suppress body fat accumulation |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6354691B2 (enrdf_load_stackoverflow) | 1988-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100474625B1 (ko) | 말토덱스트린및아미노산을함유하는복막투석용액 | |
| KR0145289B1 (ko) | 히스티딘 완충 복막 투석 용액 | |
| AU754537B2 (en) | Novel pharmaceutical composition for use in emergency treatment and preparation method thereof | |
| US5112865A (en) | Pharmaceutical compositions containing a derivative of 3-hydroxybutanoic acid chosen from oligomers of this acid and esters of this acid or of these oligomers with 1,3-butanediol | |
| CA1187801A (en) | Dialysis solution containing glycerol | |
| Weichselbaum et al. | Comparative utilization of fructose and glucose given intravenously. | |
| JP4638106B2 (ja) | 医薬的使用のための溶液中における浸透圧剤としての、ｌ−カルニチンおよびそのアルカノイル誘導体の使用 | |
| DE69332106T3 (de) | Lösung für die Peritonealdialyse | |
| Worthley | Hyperosmolar coma treated with intravenous sterile water: a study of three cases | |
| DE60022759T2 (de) | Erythropoietin formulierungen des mehrfachdosis-typs | |
| Rottembourg et al. | Clinical aspects of continuous ambulatory and continuous cyclic peritoneal dialysis in diabetic patients | |
| JPS6251616A (ja) | 糖質輸液剤 | |
| CN1244403A (zh) | 一种参麦等渗注射液的制备方法 | |
| JPH02191212A (ja) | ３―ヒドロキシ酪酸（β―ヒドロキシ酪酸）及びその塩からなる輸液製剤 | |
| RU2114617C1 (ru) | Антидиабетическое средство на основе янтарной кислоты | |
| JP3644024B2 (ja) | 腹膜透析液 | |
| JP3572085B2 (ja) | 栄養輸液剤 | |
| JP3643879B2 (ja) | 電解質輸液組成物 | |
| JPS61200908A (ja) | 糖質輸液 | |
| JP3214116B2 (ja) | 術中輸液製剤 | |
| KR20150120277A (ko) | C형 바이러스 간염 치료제 | |
| Powell | Jugular vein obstruction caused by turning of the head: CA Gooding and GK Stimac. Am J Roentgenol 142: 403–406,(February), 1984 | |
| Raker | Blood-glucose concentrations during anaesthesia in children. Effects of Starvation and perioperative fluid therapy: K. Nilsson, LE Larsson, S. Andreasson, et al. Br J Anaesth 56: 375–378,(April), 1984 | |
| Whalen | Human bites in children: P. Schweih and G. Fleisher. Pediatr Emerg Care 1: 51–53,(June), 1985 | |
| Dickson | Accidental ingestion of sterilizing tablets by children: MZ Siodlak, MJ Glesson, and CL Wengraf. Br Med J 290: 1707–1708,(June), 1985 |